Hypertension in men and an increasing number of cardiometabolic criteria were associated with higher risk for advanced fibrosis and at-risk MASH.
Hepta, a liquid biopsy company developing blood tests for chronic disease, today announced clinical data showing its blood ...
The Enhanced Liver Fibrosis (ELF) Test from Siemens Healthineers is now available in the United States, providing broad clinical access to the minimally invasive prognostic tool. Currently, the ELF ...
Siemens is launching its Enhanced Liver Fibrosis (ELF) diagnostic in the U.S. this week to help test patients with chronic liver disease. This new testing service comes out of the Siemens Healthcare ...
Background: FibroTest (FT) is the most frequently used serum fibrosis marker and consists of an algorithm of five fibrosis markers (alfa2-macroglobulin, apolipoproteinA1, haptoglobin, GGT, bilirubin).
The Enhanced Liver Fibrosis (ELF) is the first prognostic tool for patients with advanced fibrosis (F3 or F4) due to non-alcoholic steatohepatitis (NASH) to be granted De Novo marketing authorization.
At present, transient elastography and the serum marker FibroTest are the most intensively evaluated non-invasive methods for the assessment of liver fibrosis. The results of the present study for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results